Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting

Sho, Takuya; Suda, Goki; Ogawa, Koji et al.

JGH open, 2020, 4(1), 54-60

Permalink : https://hdl.handle.net/2115/77028

このアイテムのアクセス数:640件（2026-08-09 22:51 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
https://doi.org/10.1002/jgh3.12209     42

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/77028
タイトル
Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting
著者
Sho, Takuya ; Suda, Goki ; Ogawa, Koji ; Kimura, Megumi ; Shimazaki, Tomoe ; Maehara, Osamu ; Shigesawa, Taku ; Suzuki, Kazuharu ; Nakamura, Akihisa ; Ohara, Masatsugu ; Umemura, Machiko ; Kawagishi, Naoki ; Natsuizaka, Mitsuteru ; Nakai, Masato ; Morikawa, Kenichi ; Furuya, Ken ; Baba, Masaru ; Yamamoto, Yoshiya ; Kobayashi, Tomoe ; Meguro, Takashi ; Saga, Akiyoshi ; Miyagishima, Takuto ; Yokoo, Hideki ; Kamiyama, Toshiya ; Taketomi, Akinobu ; Sakamoto, Naoya
著者名
Sho, Takuya
e-Rad_Researcher
20447460
著者名
Suda, Goki
e-Rad_Researcher
20735188
著者名
Ogawa, Koji
著者名
Kimura, Megumi
著者名
Shimazaki, Tomoe
著者名
Maehara, Osamu
著者名
Shigesawa, Taku
著者名
Suzuki, Kazuharu
著者名
Nakamura, Akihisa
著者名
Ohara, Masatsugu
著者名
Umemura, Machiko
e-Rad_Researcher
00333807
著者名
Kawagishi, Naoki
e-Rad_Researcher
80642446
著者名
Natsuizaka, Mitsuteru
著者名
Nakai, Masato
著者名
Morikawa, Kenichi
著者名
Furuya, Ken
著者名
Baba, Masaru
著者名
Yamamoto, Yoshiya
著者名
Kobayashi, Tomoe
著者名
Meguro, Takashi
著者名
Saga, Akiyoshi
著者名
Miyagishima, Takuto
e-Rad_Researcher
70399947
著者名
Yokoo, Hideki
e-Rad_Researcher
80322816
著者名
Kamiyama, Toshiya
e-Rad_Researcher
70363364
著者名
Taketomi, Akinobu
e-Rad_Researcher
10334418
著者名
Sakamoto, Naoya
言語
英語
キーワード
early response
lenvatinib
real world
REFLECT
発行日
2020-02
出版者
John Wiley & Sons
収録物名
JGH open
巻(号)
4(1)
ページ
54-60
抄録
Background and AimLenvatinib has been recently approved as a first-line systematic therapy for patients with advanced hepatocellular carcinoma (HCC) based on the results of the phase 3 clinical trial REFLECT. This trial excluded patients with a history of systemic chemotherapy, bile duct invasion, and Child-Pugh grade B. We aimed to investigate the efficacy and safety of lenvatinib for these patients and in the real-world setting. MethodsAmong patients who were administered lenvatinib for advanced HCC between April and October 2018 in Hokkaido University Hospital and related hospitals, we evaluated those who were followed for more than 2 months and whose treatment response was evaluated via dynamic computed tomography at baseline and 2 months after treatment initiation. Meanwhile, patients were excluded if they had decompensated liver cirrhosis, were followed up less than 2 months, or were not evaluated at 2 months. Patients were also stratified according to compliance with the REFLECT inclusion criteria for further analysis. ResultsA total of 41 patients were included; more than 50% did not meet the REFLECT inclusion criteria. In total, 5 (12.2%), 20 (48.8%), 12 (29.3%), and 4 (9.3%) showed complete response, partial response, stable disease, and progressive disease, respectively. The objective response rate was 61.2%. The objective response rate and disease control rate were similar between patients who did and did not meet the REFLECT inclusion criteria. Moreover, the safety profile was also similar between the two patient groups. ConclusionLenvatinib showed high early response rate and tolerability in patients with advanced HCC. Favorable outcomes were similarly observed in patients who did not meet the REFLECT inclusion criteria.
資源タイプ
学術雑誌論文
出版タイプ
Version of Record
権利情報
Creative Commons Attribution 4.0 International
PISSN
2397-9070
関連情報 (isIdenticalTo)
出版社版DOI
https://doi.org/10.1002/jgh3.12209